Search for: "IN RE KUBIN"
Results 21 - 40
of 78
Sorted by Relevance
|
Sort by Date
17 Apr 2009, 8:14 pm
Kevin Noonan, Andrew Williams, and Donald Zuhn of McDonnell Boehnen Hulbert and Berghoff LLP will discuss recent decisions on obviousness (In re Kubin), written description (Ariad v. [read post]
21 May 2010, 6:21 pm
See Graham, supra; In re Kubin, 561 F.3d 1351, 1355 (Fed. [read post]
20 Apr 2009, 8:32 am
Here’s a biotech countdown from the past week: Six blog reactions were collected to In re Kubin, a U.S. patent case that invalidated one of Amgen’s DNA patent. [read post]
9 Jan 2013, 11:01 am
Cir. 2009) (citing In re Kubin, 561 F.3d 1351, 1360 (Fed. [read post]
9 Apr 2009, 2:46 pm
In In re Kubin (08-1184), the US Court of Appeals for the Federal Circuit held that the US Patent and Trademark Office's Board of Patent Appeals and Interferences was correct to hold claims as unpatentably obvious when applicants use "conventional techniques" to make an invention. [read post]
22 Aug 2020, 2:12 pm
Kubin, 561 F.3d at 1359. [read post]
5 Jul 2009, 3:02 pm
"Recall that LawPundit has posted previously and quite definitely about the bad judgement involved in permitting the biotech patenting of human genes:In re Kubin : Hitting the NAIL on the Head : Sequencing Poor Federal Circuit Court Decisions out of the Biotechnology Patent Genome via KSR and/or Bilski ReasoningFederal Circuit affirms In re Kubin and puts sensible limits on Biotechnology Patents pursuant to the KSR obviousness standard, thus negating Deuel… [read post]
26 Apr 2009, 6:02 pm
From the Federal Circuit's In re Kubin decision (citing In re O'Farrell): Specifically, this court observed that an obviousness finding was appropriate where the prior art "contained detailed enabling methodology for practicing the claimed invention, a suggestion to modify the prior art to practice the claimed invention, and evidence suggesting that it would be successful. [read post]
28 Aug 2009, 9:55 pm
The conference will allow attendees to collect up-to-date information and insights on: • Recent changes in policy and patentability criteria: Hear directly from the EPO; • The latest EPO decisions impacting key aspects of biotech patenting such as methods of surgery and new standards on double patenting and prior art; • Major U.S. case law developments and how they… [read post]
21 Sep 2012, 11:02 pm
In re Kubin, 561 F.3d 1351, 1360 (Fed. [read post]
13 Jul 2018, 5:48 pm
” In re Kubin, 561 F.3d 1351, 1355 (Fed.Cir. 2009). [read post]
12 Apr 2014, 6:39 am
In re Kubin, 561 F.3d1351, 1359 (Fed. [read post]
1 Jan 2008, 6:49 pm
LG – Patent “Exhaustion” McFarling – Patent “Exhaustion” Kubin – Biotech Obviousness; Enzo Disclosure Classen v. [read post]
2 Sep 2008, 10:32 pm
KSR, In re Kubin, In re MedImmune, In re Duel and other crucial cases: how these court decisions are being interpreted and applied by the USPTO and the Board of Patent Appeals and Interference The status of Follow-On Biologics: the European Patent Office has already taken steps to introduce them into the marketplace.With growing demand for generic products in the US, can the FDA and USPTO be far behind? [read post]
3 May 2010, 5:08 pm
Cir. 2009); In re Kubin, 561 F.3d 1351, 1359, (Fed. [read post]
9 Apr 2009, 7:52 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: US CAFC clarifies obviousness standard in context of cDNA cloning invention: In re Kubin (Holman's Biotech IP Blog) (Patent Docs) (Hal Wegner) (Philip Brooks' Patent Infringement Updates) (Patently-O) (Patent Docs) Xigris (Drotrecogin alfa) –US: CAFC: Pioneering claims require more expansive written… [read post]
8 Apr 2009, 8:57 pm
On April 3, 2009, the Federal Circuit provided further commentary on the “obvious to try” test in In re Kubin (Fed. [read post]
3 Mar 2008, 9:27 pm
Cir. 2005). ]The Kubin decision had text about the CAFC decision In re Deuel:Appellants heavily rely on Deuel. [read post]
16 Jan 2009, 5:00 am
(IP finance) US: Medarex, Eurand and Alexion file actions against Director Dudas seeking revised patent term adjustment determinations (Patent Docs) US: Kubin panel questions motivation behind reversal in new Written Description Training Materials (Patent Docs) US: The obviousness of DNA - Federal Circuit heard oral argument for In re Kubin last week (Patent Docs) Products Antara (Fenofibrate) – US: Oscient and Ethypharm file patent infringement suit… [read post]
11 Apr 2023, 2:44 pm
Cir. 2020) (quoting In re Kubin, 561 F.3d 1351, 1357 (Fed. [read post]
